Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Solomon

Showing results (1621-1630 of 1,873) with videos related to

Pageof 188
Sort By:
Journal of the American College of Cardiology|May 27, 2026
Exploration of Arrhythmia Burden in Cardiac Amyloidosis Using Implantable Loop Recorders - The EXCALIBUR studyAdam Ioannou, Rishi Patel, Josephine Mansell, et al.
Cardiovascular Drugs and Therapy|July 24, 2017
Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics ConferenceThomas J Povsic, Rob Scott, Kenneth W Mahaffey, et al.
European Journal of Heart Failure|June 16, 2020
Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HFPooja Dewan, Scott D Solomon, Pardeep S Jhund, et al.
Annals of Internal Medicine|April 25, 2022
Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF TrialJawad H Butt, Pooja Dewan, Béla Merkely, et al.
JAMA Cardiology|March 31, 2021
Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure TrialJawad H Butt, Kieran F Docherty, Mark C Petrie, et al.
Circulation|April 9, 2021
Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HFPardeep S Jhund, Piotr Ponikowski, Kieran F Docherty, et al.
Circulation|November 19, 2019
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF TrialMikhail N Kosiborod, Pardeep S Jhund, Kieran F Docherty, et al.
American Heart Journal|August 1, 2025
A pragmatic individually randomized trial to evaluate the effectiveness of high-dose vs standard-dose influenza vaccine in older adults: Rationale and design of the DANFLU-2 trialNiklas Dyrby Johansen, Daniel Modin, Matthew M Loiacono, et al.
JACC. Heart Failure|April 4, 2020
Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection FractionJonathan W Cunningham, Muthiah Vaduganathan, Brian L Claggett, et al.
Molecular Psychiatry|June 20, 2012
Pooling/bootstrap-based GWAS (pbGWAS) identifies new loci modifying the age of onset in PSEN1 p.Glu280Ala Alzheimer's diseaseJ I Vélez, S C Chandrasekharappa, E Henao, et al.
Pageof 188

Showing results (1621-1630 of 1,873) with videos related to

Sort By:
Pageof 188
Journal of the American College of Cardiology|May 27, 2026
Exploration of Arrhythmia Burden in Cardiac Amyloidosis Using Implantable Loop Recorders - The EXCALIBUR studyAdam Ioannou, Rishi Patel, Josephine Mansell, et al.
Cardiovascular Drugs and Therapy|July 24, 2017
Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics ConferenceThomas J Povsic, Rob Scott, Kenneth W Mahaffey, et al.
European Journal of Heart Failure|June 16, 2020
Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HFPooja Dewan, Scott D Solomon, Pardeep S Jhund, et al.
Annals of Internal Medicine|April 25, 2022
Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF TrialJawad H Butt, Pooja Dewan, Béla Merkely, et al.
JAMA Cardiology|March 31, 2021
Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure TrialJawad H Butt, Kieran F Docherty, Mark C Petrie, et al.
Circulation|April 9, 2021
Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HFPardeep S Jhund, Piotr Ponikowski, Kieran F Docherty, et al.
Circulation|November 19, 2019
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF TrialMikhail N Kosiborod, Pardeep S Jhund, Kieran F Docherty, et al.
American Heart Journal|August 1, 2025
A pragmatic individually randomized trial to evaluate the effectiveness of high-dose vs standard-dose influenza vaccine in older adults: Rationale and design of the DANFLU-2 trialNiklas Dyrby Johansen, Daniel Modin, Matthew M Loiacono, et al.
JACC. Heart Failure|April 4, 2020
Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection FractionJonathan W Cunningham, Muthiah Vaduganathan, Brian L Claggett, et al.
Molecular Psychiatry|June 20, 2012
Pooling/bootstrap-based GWAS (pbGWAS) identifies new loci modifying the age of onset in PSEN1 p.Glu280Ala Alzheimer's diseaseJ I Vélez, S C Chandrasekharappa, E Henao, et al.
Pageof 188